Mechanism

How it works

Orexin B binds with approximately equal affinity to both OX1R and OX2R G-protein-coupled receptors, though it shows a slight preference for OX2R. Upon receptor activation, downstream signaling involves Gq/11-mediated phospholipase C activation, IP3-driven intracellular calcium release, and activation of PKC pathways, as well as Gs-mediated cAMP elevation. These cascades increase the excitability of wake-promoting neurons in the locus coeruleus, dorsal raphe, and tuberomammillary nucleus, sustaining arousal and suppressing transitions into REM sleep.

Reported in research

Benefits

Promotes and stabilizes wakefulness, potentially relevant to narcolepsy and hypersomnia research
May enhance cognitive performance and alertness by activating noradrenergic and serotonergic arousal circuits
Modulates appetite and energy expenditure through hypothalamic feeding circuits
Preclinical evidence suggests roles in stress response regulation and mood stabilization

Context, not a prescription

Dosing

Typical range: Research dosing not established in humans; animal studies typically use 0.3–3 nmol ICV or 1–10 µg/kg intranasally (Nasal, Intramuscular)
Cycle length: Acute use in research settings; no established chronic cycle
Half-life: ~10–20 minutes (endogenous peptide; rapidly degraded by proteases)

Safety

Side effects & contraindications

Possible side effects

Increased heart rate and blood pressure (sympathomimetic activation)
Anxiety or hyperarousal at supraphysiological doses
Suppressed appetite or altered feeding patterns
Potential sleep architecture disruption with improper timing

Contraindications

Individuals with cardiovascular conditions or hypertension due to sympathomimetic effects
Those with anxiety disorders or hyperarousal conditions
Pregnant or breastfeeding individuals (no safety data available)
Concurrent use of stimulant medications or CNS-active compounds

Research information, not medical advice. Always consult a licensed clinician before considering any peptide.

In depth

Full profile

What it does

In animal models, increased locomotor activity, prolonged wakefulness, reduced REM sleep, and heightened attentiveness are observed.

How it works

Think of Orexin B like a traffic controller at a busy intersection. It keeps the 'stay awake' lane open and flowing, while holding back the 'fall asleep' traffic. Without it, sleep intrudes at unpredictable times, like cars running red lights.

When Orexin B is present, it activates wake-promoting brain regions and suppresses sudden transitions into sleep, especially dream sleep (REM). It also influences hunger signals, heart rate, and mood, making it a multi-purpose arousal molecule.

What to expect

Effects in research animals are observed within minutes of administration, but human data is not available for exogenous dosing.

Immediately (minutes): Rapid activation of arousal circuits; increased alertness and locomotor activity observed in preclinical models
Hours 1-4: Peak wakefulness-promoting effects; possible appetite suppression and elevated heart rate
Hours 4+: Peptide is rapidly degraded; effects diminish; normal sleep-wake cycles may resume

Good to know

Only use in a controlled research setting with proper oversight
Start with the lowest possible dose to gauge individual response
Avoid combining with stimulants like caffeine or amphetamines

Staying safe

Elevated heart rate
Reduced appetite
Feeling overly alert or restless

Avoid if you have:

People with heart conditions or high blood pressure
Those with anxiety or panic disorders
Pregnant or nursing individuals

Overview

In preclinical models, acute orexin B administration increases mean arterial pressure (+10–20 mmHg), heart rate (+20–40 bpm), locomotor activity, wakefulness duration, and suppresses both NREM and REM sleep. Metabolic effects include increased brown adipose tissue thermogenesis and modulation of insulin secretion via OX2R on pancreatic beta cells. Chronic central administration in animal models can produce lasting changes in circadian entrainment and HPA axis activity.

How it works

Orexin B functions like a master conductor of a neurochemical orchestra. It doesn't play a single instrument but rather ensures that each wake-promoting section — noradrenergic, serotonergic, histaminergic, and cholinergic — plays in coordinated synchrony. Without the conductor, individual sections fall out of time, producing the fragmented, dysregulated performance characteristic of narcolepsy.

Exogenously administered Orexin B faces significant pharmacokinetic barriers. As a peptide, it is rapidly degraded by serum proteases (t½ ~10–20 min systemic) and has poor blood-brain barrier (BBB) penetrance due to its molecular weight (~2.16 kDa) and hydrophilicity. Intranasal delivery has been explored as a non-invasive CNS delivery route, leveraging olfactory/trigeminal nerve pathways to bypass the BBB; studies in rodents (Dhuria et al., 2010, J Pharm Sci) show modest CNS delivery efficiency (~0.1–1% of dose). Intracerebroventricular (ICV) administration in animal models achieves direct CNS exposure and represents the primary research delivery method. Peripheral administration primarily affects cardiovascular and metabolic endpoints via peripheral OX receptors in the adrenal glands, pancreas, and gastrointestinal tract.

Onset & timeline

ICV administration in rodents produces locomotor activation within 2–5 minutes and sustained wakefulness for 1–2 hours post-injection. Intranasal administration in animal models shows delayed onset of 15–30 minutes with attenuated but measurable CNS effects. No validated human pharmacokinetic data for exogenous Orexin B administration is available.

Days 1-3 (acute dosing): Rapid receptor engagement; Gq/11 and Gs cascade activation; acute wakefulness promotion, cardiovascular activation, and appetite modulation. Peptide cleared within 1-2 hours post-dose.
Weeks 1-2 (repeated dosing in animal models): Potential receptor desensitization via GPCR internalization and beta-arrestin recruitment; adaptation of downstream signaling. Sustained alterations in sleep architecture and metabolic markers observed.
Weeks 2-8 (chronic preclinical studies): Persistent changes in circadian rhythm entrainment, HPA axis reactivity, and possibly neuroplastic changes in orexin-recipient nuclei. Long-term safety and receptor regulation data are limited to rodent models.

Getting the most from it

Limit research to ICV or intranasally validated delivery systems with precise dose titration
Monitor cardiovascular parameters throughout experimental sessions
Use time-controlled administration (morning/early day only) to avoid circadian disruption
Implement appropriate washout periods between dosing sessions given receptor sensitization data from animal studies

Common side effects

Sympathomimetic cardiovascular activation: tachycardia and hypertension via locus coeruleus NE release and direct peripheral adrenal OX receptor stimulation
Anorexigenic effects: paradoxical appetite suppression at supraphysiological doses despite endogenous orexin's role in feeding (dose-dependent effect reversal)
Sleep architecture disruption: prolonged sleep onset latency and REM suppression if administered near sleep time

Mechanism of action

Orexin B (Hypocretin-2) is a 28-amino acid neuropeptide cleaved from the 130-aa prepro-orexin precursor. It binds OX1R and OX2R with Kd values of approximately 250 nM and 36 nM respectively, demonstrating ~7-fold selectivity for OX2R over OX1R. OX2R couples primarily to Gq/11 (activating PLCβ → IP3/DAG → PKC and intracellular Ca²⁺ release) and Gs (adenylyl cyclase → cAMP → PKA). OX1R couples predominantly to Gq/11 with secondary Gi/o signaling. Orexinergic neurons (10,000–20,000 neurons in the lateral hypothalamic area in humans) project widely to the locus coeruleus (norepinephrine), dorsal raphe (serotonin), tuberomammillary nucleus (histamine), basal forebrain (acetylcholine), and ventral tegmental area (dopamine), collectively sustaining the ascending arousal system. Loss of these neurons — as in Type 1 narcolepsy — results in cataplexy and sleep fragmentation.

Exogenously administered Orexin B faces significant pharmacokinetic barriers. As a peptide, it is rapidly degraded by serum proteases (t½ ~10–20 min systemic) and has poor blood-brain barrier (BBB) penetrance due to its molecular weight (~2.16 kDa) and hydrophilicity. Intranasal delivery has been explored as a non-invasive CNS delivery route, leveraging olfactory/trigeminal nerve pathways to bypass the BBB; studies in rodents (Dhuria et al., 2010, J Pharm Sci) show modest CNS delivery efficiency (~0.1–1% of dose). Intracerebroventricular (ICV) administration in animal models achieves direct CNS exposure and represents the primary research delivery method. Peripheral administration primarily affects cardiovascular and metabolic endpoints via peripheral OX receptors in the adrenal glands, pancreas, and gastrointestinal tract.

Pharmacodynamics

ICV administration in rodents produces locomotor activation within 2–5 minutes and sustained wakefulness for 1–2 hours post-injection. Intranasal administration in animal models shows delayed onset of 15–30 minutes with attenuated but measurable CNS effects. No validated human pharmacokinetic data for exogenous Orexin B administration is available.

In preclinical models, acute orexin B administration increases mean arterial pressure (+10–20 mmHg), heart rate (+20–40 bpm), locomotor activity, wakefulness duration, and suppresses both NREM and REM sleep. Metabolic effects include increased brown adipose tissue thermogenesis and modulation of insulin secretion via OX2R on pancreatic beta cells. Chronic central administration in animal models can produce lasting changes in circadian entrainment and HPA axis activity.

Timeline

Days 1-3 (acute dosing): Rapid receptor engagement; Gq/11 and Gs cascade activation; acute wakefulness promotion, cardiovascular activation, and appetite modulation. Peptide cleared within 1-2 hours post-dose.
Weeks 1-2 (repeated dosing in animal models): Potential receptor desensitization via GPCR internalization and beta-arrestin recruitment; adaptation of downstream signaling. Sustained alterations in sleep architecture and metabolic markers observed.
Weeks 2-8 (chronic preclinical studies): Persistent changes in circadian rhythm entrainment, HPA axis reactivity, and possibly neuroplastic changes in orexin-recipient nuclei. Long-term safety and receptor regulation data are limited to rodent models.

Comparisons

Orexin B — effectiveness Moderate (preclinical only), safety Moderate, cost $$$, High complexity (ICV/intranasal research only) to use
Orexin A — effectiveness Moderate (broader receptor profile), safety Moderate, cost $$$, High complexity to use
Semax (ACTH 4-10 analog) — effectiveness Moderate (cognition focus), safety Good, cost $$, Medium (intranasal) to use

Adverse effects

Common:

Sympathomimetic cardiovascular activation: tachycardia and hypertension via locus coeruleus NE release and direct peripheral adrenal OX receptor stimulation
Anorexigenic effects: paradoxical appetite suppression at supraphysiological doses despite endogenous orexin's role in feeding (dose-dependent effect reversal)
Sleep architecture disruption: prolonged sleep onset latency and REM suppression if administered near sleep time

Rare:

Hyperthermia secondary to BAT thermogenesis activation (observed in rodent high-dose ICV studies)
Stress hormone (cortisol/corticosterone) elevation via HPA axis activation

Contraindications & risk mitigation

Contraindicated in:

Individuals with pre-existing sympathomimetic sensitivity or labile hypertension
Subjects on MAO inhibitors or sympathomimetic compounds (risk of additive cardiovascular effects)
Individuals with history of anxiety disorders (orexin system dysregulation implicated in panic circuitry)
Those with metabolic disorders sensitive to glucose regulation changes

Limit research to ICV or intranasally validated delivery systems with precise dose titration
Monitor cardiovascular parameters throughout experimental sessions
Use time-controlled administration (morning/early day only) to avoid circadian disruption
Implement appropriate washout periods between dosing sessions given receptor sensitization data from animal studies

Qué hace

In animal models, increased locomotor activity, prolonged wakefulness, reduced REM sleep, and heightened attentiveness are observed.

Cómo funciona

Think of Orexin B like a traffic controller at a busy intersection. It keeps the 'stay awake' lane open and flowing, while holding back the 'fall asleep' traffic. Without it, sleep intrudes at unpredictable times, like cars running red lights.

When Orexin B is present, it activates wake-promoting brain regions and suppresses sudden transitions into sleep, especially dream sleep (REM). It also influences hunger signals, heart rate, and mood, making it a multi-purpose arousal molecule.

Qué esperar

Effects in research animals are observed within minutes of administration, but human data is not available for exogenous dosing.

Immediately (minutes): Rapid activation of arousal circuits; increased alertness and locomotor activity observed in preclinical models
Hours 1-4: Peak wakefulness-promoting effects; possible appetite suppression and elevated heart rate
Hours 4+: Peptide is rapidly degraded; effects diminish; normal sleep-wake cycles may resume

Bueno saber

Only use in a controlled research setting with proper oversight
Start with the lowest possible dose to gauge individual response
Avoid combining with stimulants like caffeine or amphetamines

Manteniéndose seguro

Elevated heart rate
Reduced appetite
Feeling overly alert or restless

Evitar si tienes:

People with heart conditions or high blood pressure
Those with anxiety or panic disorders
Pregnant or nursing individuals

Descripción general

In preclinical models, acute orexin B administration increases mean arterial pressure (+10–20 mmHg), heart rate (+20–40 bpm), locomotor activity, wakefulness duration, and suppresses both NREM and REM sleep. Metabolic effects include increased brown adipose tissue thermogenesis and modulation of insulin secretion via OX2R on pancreatic beta cells. Chronic central administration in animal models can produce lasting changes in circadian entrainment and HPA axis activity.

Cómo funciona

Orexin B functions like a master conductor of a neurochemical orchestra. It doesn't play a single instrument but rather ensures that each wake-promoting section — noradrenergic, serotonergic, histaminergic, and cholinergic — plays in coordinated synchrony. Without the conductor, individual sections fall out of time, producing the fragmented, dysregulated performance characteristic of narcolepsy.

Exogenously administered Orexin B faces significant pharmacokinetic barriers. As a peptide, it is rapidly degraded by serum proteases (t½ ~10–20 min systemic) and has poor blood-brain barrier (BBB) penetrance due to its molecular weight (~2.16 kDa) and hydrophilicity. Intranasal delivery has been explored as a non-invasive CNS delivery route, leveraging olfactory/trigeminal nerve pathways to bypass the BBB; studies in rodents (Dhuria et al., 2010, J Pharm Sci) show modest CNS delivery efficiency (~0.1–1% of dose). Intracerebroventricular (ICV) administration in animal models achieves direct CNS exposure and represents the primary research delivery method. Peripheral administration primarily affects cardiovascular and metabolic endpoints via peripheral OX receptors in the adrenal glands, pancreas, and gastrointestinal tract.

Inicio y cronología

ICV administration in rodents produces locomotor activation within 2–5 minutes and sustained wakefulness for 1–2 hours post-injection. Intranasal administration in animal models shows delayed onset of 15–30 minutes with attenuated but measurable CNS effects. No validated human pharmacokinetic data for exogenous Orexin B administration is available.

Days 1-3 (acute dosing): Rapid receptor engagement; Gq/11 and Gs cascade activation; acute wakefulness promotion, cardiovascular activation, and appetite modulation. Peptide cleared within 1-2 hours post-dose.
Weeks 1-2 (repeated dosing in animal models): Potential receptor desensitization via GPCR internalization and beta-arrestin recruitment; adaptation of downstream signaling. Sustained alterations in sleep architecture and metabolic markers observed.
Weeks 2-8 (chronic preclinical studies): Persistent changes in circadian rhythm entrainment, HPA axis reactivity, and possibly neuroplastic changes in orexin-recipient nuclei. Long-term safety and receptor regulation data are limited to rodent models.

Cómo aprovecharlo al máximo

Limit research to ICV or intranasally validated delivery systems with precise dose titration
Monitor cardiovascular parameters throughout experimental sessions
Use time-controlled administration (morning/early day only) to avoid circadian disruption
Implement appropriate washout periods between dosing sessions given receptor sensitization data from animal studies

Efectos secundarios comunes

Sympathomimetic cardiovascular activation: tachycardia and hypertension via locus coeruleus NE release and direct peripheral adrenal OX receptor stimulation
Anorexigenic effects: paradoxical appetite suppression at supraphysiological doses despite endogenous orexin's role in feeding (dose-dependent effect reversal)
Sleep architecture disruption: prolonged sleep onset latency and REM suppression if administered near sleep time

Mecanismo de acción

Orexin B (Hypocretin-2) is a 28-amino acid neuropeptide cleaved from the 130-aa prepro-orexin precursor. It binds OX1R and OX2R with Kd values of approximately 250 nM and 36 nM respectively, demonstrating ~7-fold selectivity for OX2R over OX1R. OX2R couples primarily to Gq/11 (activating PLCβ → IP3/DAG → PKC and intracellular Ca²⁺ release) and Gs (adenylyl cyclase → cAMP → PKA). OX1R couples predominantly to Gq/11 with secondary Gi/o signaling. Orexinergic neurons (10,000–20,000 neurons in the lateral hypothalamic area in humans) project widely to the locus coeruleus (norepinephrine), dorsal raphe (serotonin), tuberomammillary nucleus (histamine), basal forebrain (acetylcholine), and ventral tegmental area (dopamine), collectively sustaining the ascending arousal system. Loss of these neurons — as in Type 1 narcolepsy — results in cataplexy and sleep fragmentation.

Exogenously administered Orexin B faces significant pharmacokinetic barriers. As a peptide, it is rapidly degraded by serum proteases (t½ ~10–20 min systemic) and has poor blood-brain barrier (BBB) penetrance due to its molecular weight (~2.16 kDa) and hydrophilicity. Intranasal delivery has been explored as a non-invasive CNS delivery route, leveraging olfactory/trigeminal nerve pathways to bypass the BBB; studies in rodents (Dhuria et al., 2010, J Pharm Sci) show modest CNS delivery efficiency (~0.1–1% of dose). Intracerebroventricular (ICV) administration in animal models achieves direct CNS exposure and represents the primary research delivery method. Peripheral administration primarily affects cardiovascular and metabolic endpoints via peripheral OX receptors in the adrenal glands, pancreas, and gastrointestinal tract.

Farmacodinamia

ICV administration in rodents produces locomotor activation within 2–5 minutes and sustained wakefulness for 1–2 hours post-injection. Intranasal administration in animal models shows delayed onset of 15–30 minutes with attenuated but measurable CNS effects. No validated human pharmacokinetic data for exogenous Orexin B administration is available.

In preclinical models, acute orexin B administration increases mean arterial pressure (+10–20 mmHg), heart rate (+20–40 bpm), locomotor activity, wakefulness duration, and suppresses both NREM and REM sleep. Metabolic effects include increased brown adipose tissue thermogenesis and modulation of insulin secretion via OX2R on pancreatic beta cells. Chronic central administration in animal models can produce lasting changes in circadian entrainment and HPA axis activity.

Cronología

Days 1-3 (acute dosing): Rapid receptor engagement; Gq/11 and Gs cascade activation; acute wakefulness promotion, cardiovascular activation, and appetite modulation. Peptide cleared within 1-2 hours post-dose.
Weeks 1-2 (repeated dosing in animal models): Potential receptor desensitization via GPCR internalization and beta-arrestin recruitment; adaptation of downstream signaling. Sustained alterations in sleep architecture and metabolic markers observed.
Weeks 2-8 (chronic preclinical studies): Persistent changes in circadian rhythm entrainment, HPA axis reactivity, and possibly neuroplastic changes in orexin-recipient nuclei. Long-term safety and receptor regulation data are limited to rodent models.

Comparaciones

Orexin B — efectividad Moderate (preclinical only), seguridad Moderate, costo $$$, High complexity (ICV/intranasal research only) de usar
Orexin A — efectividad Moderate (broader receptor profile), seguridad Moderate, costo $$$, High complexity de usar
Semax (ACTH 4-10 analog) — efectividad Moderate (cognition focus), seguridad Good, costo $$, Medium (intranasal) de usar

Efectos adversos

Comunes:

Sympathomimetic cardiovascular activation: tachycardia and hypertension via locus coeruleus NE release and direct peripheral adrenal OX receptor stimulation
Anorexigenic effects: paradoxical appetite suppression at supraphysiological doses despite endogenous orexin's role in feeding (dose-dependent effect reversal)
Sleep architecture disruption: prolonged sleep onset latency and REM suppression if administered near sleep time

Raros:

Hyperthermia secondary to BAT thermogenesis activation (observed in rodent high-dose ICV studies)
Stress hormone (cortisol/corticosterone) elevation via HPA axis activation

Contraindicaciones y mitigación de riesgos

Contraindicado en:

Individuals with pre-existing sympathomimetic sensitivity or labile hypertension
Subjects on MAO inhibitors or sympathomimetic compounds (risk of additive cardiovascular effects)
Individuals with history of anxiety disorders (orexin system dysregulation implicated in panic circuitry)
Those with metabolic disorders sensitive to glucose regulation changes

Limit research to ICV or intranasally validated delivery systems with precise dose titration
Monitor cardiovascular parameters throughout experimental sessions
Use time-controlled administration (morning/early day only) to avoid circadian disruption
Implement appropriate washout periods between dosing sessions given receptor sensitization data from animal studies

Reference data

Specifications

Molecular formula: C₁₀₄H₁₅₆N₂₆O₂₅S
Molecular weight: 2159.56 Da
Half-life: ~10–20 minutes (endogenous peptide; rapidly degraded by proteases)
Route: Nasal, Intramuscular
Cycle length: Acute use in research settings; no established chronic cycle
Storage: Store lyophilized powder at -20°C, protected from light and moisture. Once reconstituted, store at 4°C and use within 48–72 hours. Avoid repeated freeze-thaw cycles.
Legal status: Research chemical; not approved for human therapeutic use by the FDA or EMA. Legal to purchase for research purposes in most jurisdictions.

FAQ

Common questions

How does Orexin B differ pharmacologically from Orexin A?

Orexin A (33 aa, two disulfide bridges) binds OX1R and OX2R with similar affinity (Kd ~20 nM each), while Orexin B (28 aa, linear) shows ~7-fold selectivity for OX2R. This receptor selectivity means their downstream signaling profiles and anatomical targets partially diverge. OX1R is more prominent in the locus coeruleus (NE-mediated arousal and stress), while OX2R is dominant in the tuberomammillary nucleus (histamine-mediated arousal) and has greater relevance to narcolepsy pathophysiology. Orexin A crosses the BBB slightly more efficiently due to its structural differences.

What is the clinical relevance of Orexin B research?

The orexin system is the pharmacological basis of several approved narcolepsy treatments and insomnia medications. Dual orexin receptor antagonists (DORAs) like suvorexant (FDA-approved 2014) and lemborexant block OX1R/OX2R to treat insomnia. Orexin B research informs the mechanistic understanding of these drugs and guides development of selective OX2R agonists for narcolepsy. The exogenous peptide itself is not in clinical trials but serves as an important tool compound.

What delivery limitations exist for systemic or intranasal Orexin B?

Systemic peptide delivery is severely hampered by rapid enzymatic degradation (t½ ~10-20 min), poor BBB penetrance, and first-pass catabolism. Intranasal delivery exploits olfactory nerve transport to partially bypass the BBB, with documented CNS delivery in rodents (Dhuria SV et al., J Pharm Sci 2010;99:1654-73), but bioavailability remains low and variable. Small-molecule OX2R agonists and peptidomimetics with improved CNS penetrance are active areas of pharmaceutical development.

What is the evidence level?

This compound is classified as Animal data. Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.

Research

Research & sources

Animal data

Current evidence for Orexin B is rated as Animal data. Research is based primarily on animal models.

1. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior (1998) — Cell. 92(4):573-585. Sakurai T et al. PMID: 9491897
2. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity (1998) — PNAS. 95(1):322-327. de Lecea L et al. PMID: 9390374
3. Intranasal delivery to the central nervous system: Mechanisms and experimental considerations (2010) — J Pharm Sci. 99(4):1654-1673. Dhuria SV et al. PMID: 19697349
4. Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial (2012) — Sci Transl Med. 4(129):129ra43. Bettica P et al. PMID: 22491949
5. The role of orexin in regulating the sleep-wake cycle and its implications for narcolepsy (2017) — Sleep Med Rev. 35:1-13. Kornum BR et al. PMID: 27816503

Explore

Often discussed alongside

Selank · cognition Semax · cognition CJC-1295 · growth GHRP-6 · growth